Product was the largest of Natera, Inc.’s 2 reported lines in fiscal 2025, at $2.30B — 100% of $2.31B.
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product | $797.31M | $1.07B | $1.69B | $2.30B | ||||||
| Panorama Nipt | — | — | — | — | ||||||
| Hcs | — | — | — | — | ||||||
| Licensing & Other | $22.92M | $14.05M | $11.84M | $10.29M | ||||||
| Other Genetic Tests | — | — | — | — | ||||||
| Upfront License & Constellation And Paternity | — | — | — | — | ||||||
| Constellation | — | — | — | — | ||||||
| Other, Licensing & Other | — | — | — | — | ||||||
| Total | $820.22M | $1.08B | $1.70B | $2.31B |
In fiscal 2025, which ended December 31, 2025, the 2 revenue lines Natera, Inc. reported in this breakdown added up to $2.31B. That was up 35.9% from $1.70B in fiscal 2024. Product was the largest revenue line, at $2.30B or 99.6% of the total, followed by Licensing & Other ($10.29M, 0.4%).
Over fiscal 2022 to 2025, revenue across these revenue lines went from $820.22M to $2.31B, a compound annual growth rate of 41.1%. Product's share of the total rose from 97.2% to 99.6% over the same years.
The table also keeps 6 revenue lines that Natera, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2016 to 2025, as reported in Natera, Inc.'s annual filings.
United States was the largest of Natera, Inc.’s 4 reported lines in fiscal 2025, at $2.26B — 98% of $2.31B.
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $785.85M | $1.05B | $1.66B | $2.26B | |||||||||
| Europe, Middle East, India, & Africa | $16.64M | $22.81M | $23.88M | $24.48M | |||||||||
| Europe, Middle East, India, Africa | — | — | — | — | |||||||||
| Asia Pacific & Other | $14.03M | $7.22M | $8.66M | $8.01M | |||||||||
| Other | — | — | — | — | |||||||||
| Americas, Excluding U.S | $3.71M | $4.91M | $6.62M | $9.35M | |||||||||
| Total | $820.22M | $1.08B | $1.70B | $2.31B |
In fiscal 2025, which ended December 31, 2025, the 4 regions Natera, Inc. reported in this breakdown added up to $2.31B. That was up 35.9% from $1.70B in fiscal 2024. United States was the largest region, at $2.26B or 98.2% of the total, followed by Europe, Middle East, India, & Africa ($24.48M, 1.1%) and Americas, Excluding U.S ($9.35M, 0.4%). Together, the two largest regions made up 99.2% of this total.
Over fiscal 2022 to 2025, revenue across these regions went from $820.22M to $2.31B, a compound annual growth rate of 41.1%. United States' share of the total rose from 95.8% to 98.2% over the same years.
The table also keeps 2 regions that Natera, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2013 to 2025, as reported in Natera, Inc.'s annual filings.
Insurance Carriers was the largest of Natera, Inc.’s 3 reported lines in fiscal 2025, at $2.17B — 94% of $2.31B.
| Customer | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Insurance Carriers | $690.75M | $954.16M | $1.57B | $2.17B | ||||||
| Laboratory & Other Partners | — | $98.89M | $97.21M | $103.11M | ||||||
| Laboratory Partners | $94.91M | — | — | — | ||||||
| Patients | $34.56M | $29.53M | $27.88M | $31.82M | ||||||
| Total | $820.22M | $1.08B | $1.70B | $2.31B |
In fiscal 2025, which ended December 31, 2025, the 3 revenue lines Natera, Inc. reported in this breakdown added up to $2.31B. That was up 35.9% from $1.70B in fiscal 2024. Insurance Carriers was the largest revenue line, at $2.17B or 94.1% of the total, followed by Laboratory & Other Partners ($103.11M, 4.5%) and Patients ($31.82M, 1.4%). Together, the two largest revenue lines made up 98.6% of this total.
Compared with fiscal 2024, Insurance Carriers grew the fastest, rising 38.1% to $2.17B.
Laboratory & Other Partners was first reported as a separate revenue line in fiscal 2023. The table also keeps 1 revenue line that Natera, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2016 to 2025, as reported in Natera, Inc.'s annual filings.
Natera, Inc. (NTRA) breaks its revenue down by revenue line and region. In fiscal 2025, its largest revenue line was Product, with $2.30B or 99.6% of the total, followed by Licensing & Other at $10.29M (0.4%).
Product was Natera, Inc.'s largest revenue line in fiscal 2025, with $2.30B in revenue, 99.6% of the $2.31B reported across its 2 revenue lines.
United States was Natera, Inc.'s largest region in fiscal 2025, with $2.26B in revenue, 98.2% of the $2.31B reported across its 4 regions.
Of the Natera, Inc. revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Insurance Carriers grew the fastest, rising 38.1% from $1.57B to $2.17B.
Every figure is taken from Natera, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2016 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.